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Either endogenous or exogenous hyperinsulinemia in the setting of insulin resistance promotes phosphorylation
and activation of farnesyltransferase, a ubiquitous enzyme that farnesylates Ras protein. Increased availability of
farnesylated Ras at the plasma membrane enhances mitogenic responsiveness of cells to various growth factors,
thus contributing to progression of cancer and atherosclerosis. This effect is specific to insulin, but is not related to
the type of insulin used. Stimulatory effect of hyperinsulinemia on farnesyltransferase in the presence of insulin
resistance represents one potential mechanism responsible for mitogenicity and atherogenicity of insulin.
Review
Insulin is a major anabolic hormone that governs carbo-
hydrate metabolism and contributes greatly to the meta-
bolism of lipids and proteins. Clinically, its primary role
is to promote glucose utilization and regulate hepatic
glucose production. At the same time, insulin is an
important, albeit mild growth factor. It promotes cell
growth, cell division, migration, and inhibits apoptosis.
These aspects of insulin action are collectively known as
the “mitogenic actions” of insulin [1] and because they
are so critical to cellular physiology, insulin is always
present in cell culture medium for the propagation and
maintenance of cells in culture. Although insulin is a
much weaker mitogen [2] than insulin-like growth fac-
tors (IGFs), platelet-derived growth factor (PDGF), vas-
cular endothelial growth factor (VEGF) and epidermal
growth factor (EGF), insulin has a very specific mito-
genic action that in fact modulates cellular responsive-
ness to all other growth factors, potentiating other
growth factors’ action [3,4].
Let us now briefly review the molecular mechanisms
by which insulin and hyperinsulinemia, particularly
when it occurs in the setting of insulin resistance, can
augment proliferative events. In order for all growth fac-
tors to stimulate mitogenesis, they must activate the
Ras-Raf-Map kinase signalling pathway (Figure 1). Ras
proteins are activated by binding guanosine triphosphate
(GTP), a process promoted by the guanine nucleotide
exchange factor, Sos. This activation can occur only if
Ras proteins are anchored at the plasma membrane
(Figure 1) [5].
Isoprenylation of Ras is the first step that commits Ras
to the process of translocation to the plasma membrane
(Figure 1) [reviewed in [6]]. Because isoprenylation of
Ras involves an attachment of a farnesyl moiety (a 15-
carbon intermediary in the cholesterol synthesis path-
way), the process is also known as farnesylation and is
activated by the enzyme farnesyltransferase (FTase). Far-
nesylated Ras is then destined to anchor at the plasma
membrane where it can be activated by growth factors.
As in the case of other growth factors, insulin acti-
vates Sos with a subsequent activation of farnesylated
Ras and other downstream targets. However, unlike
other growth factors, insulin also activates FTase by
phosphorylating its alpha subunit [7,8]. Phosphorylation
and activation of FTase increases the amounts of mem-
brane-bound, farnesylated Ras that are available for acti-
vation by other growth factors (Figure 1) [9]. This effect
of insulin on FTase is specific for insulin and is not
mimicked by other growth factors [3]. Moreover, insu-
lin’s activation of FTase requires an intact insulin, but
not IGF-1, receptor, indicating that this action is
mediated exclusively by the insulin receptor and is not
an ancillary effect of insulin/IGF-1 receptor interaction.
This was demonstrated in cells expressing the chimeric
insulin/IGF-1 receptor and in cells derived from the
insulin receptor knockout animals [3]. Furthermore, in
the context of insulin resistance, whereby the canonical
phosphatidylinositol 3-kinase (PI3K)/Akt metabolic
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pathway of insulin signalling is inhibited to various
degrees, the Ras/Raf/Map kinase mitogenic pathway of
insulin is undisturbed and possibly upregulated, leading
to increased insulin-stimulated activation of FTase with
subsequent increases in the amounts of farnesylated Ras
[8,9]. Taken together, these actions of insulin, although
normal within the context of insulin signaling enhance
the mitogenic responsiveness of cells and tissues.
The crux of the matter is that hyperinsulinemia,
whether in cell culture or in vivo (i.e., in animals and
humans), leads to the overstimulation of FTase and
excessive farnesylation and membrane association of Ras
proteins, whereby increasing cellular responsiveness to
other growth factors. This potentiation of the mitogenic
effects of other growth factors becomes critical in the
pathophysiology of progression of cancer and vascular
disease [9-11].
Several in vivo studies provided observational and
experimental support to this hypothesis. Thus, liver,
aorta, and skeletal muscle of the insulin resistant ob/ob
mice and fa/fa rats were found to contain increased
amounts of farnesylated Ras [12]. Reduction of hyperin-
sulinemia by exercise training resulted in decreased
amounts of farnesylated Ras in Zucker fa/fa rats. Induc-
tion of fetal hyperinsulinemia by direct infusion of insu-
lin into the fetus by either fetal or maternal infusions of
glucose resulted in significant increases in the activity of
FTase and the amounts of farnesylated Ras in fetal liver,
skeletal muscle, fat, and white blood cells [13]. An addi-
tional infusion of somatostatin into hyperinsulinemic
fetuses blocked fetal hyperinsulinemia and completely
prevented these increases, specifying insulin as a causa-
tive factor. In other studies, insulin infusions signifi-
cantly increased the amounts of farnesylated Ras in
white blood cells of humans, in liver samples of mice
and dogs, and in aorta samples of mice [4]. Taken
together, these findings strongly support the in vivo
relationship between insulin resistance and ability of
insulin to stimulate FTase activity.
Overall, we have observed the ability of insulin to
potentiate action of IGF-1, EGF, PDGF and VEGF in
variety of tissues, including vascular smooth muscle
cells, endothelial cells, adipocytes, fibroblasts, liver cells,
and breast cancer cells [3,4,7,9-15]. This effect of insulin
has been consistently observed whenever metabolic
insulin resistance along the PI 3-kinase pathway is pre-
sent. Thus, enhanced cellular responsiveness to growth
factors is a physiologic effect of insulin that crosses over
into a pathological one in response to hyperinsulinemia,
whether endogenous (secondary to insulin resistance) or
exogenous (secondary to chronic iatrogenic overinsulini-
zation of insulin resistant individuals).
The question that lies before us is - What are the clin-
ical implications of the hypothesis that hyperinsulinemia,
in a setting of insulin resistance, exerts significant mito-
genic and pro-atherogenic influence? Clearly, acceptance
of this postulate would demand an aggressive correction
of insulin resistance in order to diminish endogenous
compensatory hyperinsulinemia and to minimize exo-
genous hyperinsulinemia. The most appropriate way of
addressing insulin resistance therapeutically is to stress
lifestyle modifications - diet and physical activity. Diet-
ary compliance must return to its proper place as a cor-
nerstone of diabetes therapy [16], while the practice of
covering dietary indiscretions with increasing doses of
insulin should be discouraged.
Most patients with Type 2 diabetes are insulin resis-
tant, and “paying lip service” to dietary and lifestyle
therapies leads to overinsulinization. Many patients with
Type 1 diabetes who use large doses of insulin to cover
for their excessive intake of carbohydrates are also insulin
resistant. Carbohydrate counting is an extremely useful
tool in diabetes therapy, but consuming dietary carbohy-

















Figure 1 Insulin potentiates cellular mitogenic responsiveness
to growth factors (GFs). GFs (including insulin) interact with their
cognate growth factor receptors (GFR) and activate the Sos-Ras-Raf-
Map kinase branch of cellular signalling, thus promoting
mitogenesis. Initially, GFs stimulate guanine nucleotide exchange
factor (Sos) that activates Ras proteins by GTP loading. Sos
promotes exchange of GTP for GDP only if Ras is anchored at the
plasma membrane. Translocation of Ras protein to the plasma
membrane is facilitated by farnesylation of Ras, an attachment of a
farnesyl moiety to cysteine residue of Ras under the influence of
farnesyltransferase (FTase). Insulin via interaction with its specific cell
surface receptor (IR) phosphorylates and activates FTase that
increases farnesylation of Ras. Hyperinsulinemia, particularly in the
presence of insulin resistance, stimulates FTase and augments the
amount of farnesylated Ras available for GTP loading in response to
other growth factors. Greater activation of Ras leads to increased
mitogenic responsiveness of cells and tissues and enhanced
mitogenesis and subsequent pathophysiologic events. Reprinted
with permission from Diabetologia 53:229-233, 2010.
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of insulin sensitizers, such as Metformin, would be the
second best approach to improving insulin resistance.
Several studies have demonstrated the increased likeli-
hood of developing cancer in patients treated with insu-
lin or insulin secretagogues as compared with
Metformin [17,18]. The data collected between 1991
and 1996 demonstrated that patients with type 2 dia-
betes mellitus exposed to sulfonylureas and exogenous
insulin had significantly greater cancer-related mortality
than did patients treated with metformin [18]. Recently,
Jiralespong and colleagues [19] have compared the rates
of pathologic complete response (pCR) in diabetic
patients with breast cancer receiving neoadjuvant che-
motherapy and treated with metformin with those not
treated with metformin. The rate of pCR (better out-
comes) was 24% in the metformin group and 8% in the
non-metformin group (p = 0.007). While the use of
insulin did not influence the rate of pCR in the metfor-
min-treated group, its use in the non-metformin group
was associated with the lowest rate of pCR (p = 0.05).
Undoubtedly, insulin (human, pork, beef, and analo-
gues) per se does not cause cancer or atherosclerosis. If
anything, insulin, a life-saving hormone, has improved
dramatically the life expectancy of patients with dia-
betes. However, high physiological concentrations of
insulin can substantially increase cellular mitogenic
responsiveness to other growth factors and promote dis-
advantageous growth and proliferation, particularly in
the presence of insulin resistance.
The constellation of the metabolic insulin resistance
(diminished strength of insulin signaling along the PI 3-
kinase branch of its action) and hyperinsulinemia results
in overstimulation of the MAP kinase signaling branch
and chronic activation of FTase with a subsequent
increases in the amounts of farnesylated Ras. These
events augment the mitogenicity of other growth factors,
thereby promoting the progression of cancer and ather-
osclerosis [20].
In summary, the detrimental mitogenic effects of
hyperinsulinemia must be addressed along with hyper-
glycaemia when treating diabetes. Endogenous hyperin-
sulinemia must be treated by minimizing insulin
resistance with diet, exercise and insulin sensitizing
medications, whereas exogenous hyperinsulinemia must
be avoided by selecting appropriate diet and life style
while using minimal doses of insulin to achieve normo-
glycaemia. Inducing hyperinsulinemia as a price for pay-
ing “lip service” to dietary therapy is not only
inexcusable, but also potentially harmful.
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